🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you, Dr. Pisters for your inspiring vision. Our team of dedicated scientists and clinicians is committed to advancing cell therapies that will bring transformative treatments to patients with cancer, autoimmune disorders and infection diseases MD Anderson Cancer Center #CellTherapy

1/5 Thrilled to share in Nature Communications the clinical outcomes and scRNA-seq correlatives our phase I triplet immunotherapy (IO + IO + TKI) trial in clear cell #kidney cancer: nature.com/articles/s4146…

Fabulous resource preprint from Mark Yarmarkovich NYU Langone Health A pan-cancer atlas of T cell targets Integrating data from ~7500 RNA seq datasets, >1500 immunopeptidomes & >200 cancer scRNA Seq datasets. Identifying a large series of canonical & non-canonical antigens, novel self

Excited to share that my mentee, Ethan Ye Li, has received the ASCT New Investigator Award! So proud of his achievements - this is just the beginning. I have no doubt he will go on to make incredible contributions to the field! Congratulations Ethan! MD Anderson Cancer Center

Congratulations to Dr. Rafet Basar for his outstanding presentation at ASTCT on the promise of cord blood therapies. His talk highlighted our work on engineered NK cells. Grateful for his amazing contributions to the field! #NKCells #ASTCT ⁦MD Anderson Cancer Center⁩ ⁦Rafet⁩

Thank you Dr. Pisters - it was an honor to share the progress being made at the Institute for Cell Therapy Discovery & Innovation! Very grateful to Greater Houston Partnership for the opportunity to showcase our efforts to bring transformative cell therapies to patients. Looking forward to

Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells Immunity cell.com/immunity/fullt…

Please check out our paper published in Nature Medicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical

Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. simona colla at MD Anderson Cancer Center in May 2025! The speaker line up is phenomenal & the science is cutting edge. Register 👇🏼 join us & RT pls mdanderson.cloud-cme.com/course/courseo… #MDSsm

The AACR congratulates Crystal L. Mackall, MD, FAACR, who will be honored with the 2025 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology at #AACR25. brnw.ch/21wRUDO #AACRFellows Stanford Medicine Parker Institute for Cancer Immunotherapy

Brilliant work! congratulations, May Daher and simona colla and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing

Congratulations! Looking forward to your presentation. I have no doubt it’ll be amazing!

Congratulations to Alexander Biederstädt, MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells MD Anderson Cancer Center

Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" Penn Medicine @nejm #immunotherapy nejm.org/doi/full/10.10…

Hind, many congratulations on this important work & sincere thanks to the brilliant co-authors who made it possible. I’m so proud of all you’ve achieved and wish you every success as you begin your independent career. Excited to see what comes next! rdcu.be/epuy6

Many congrats Alex on this very well-deserved #societyfornaturalimmunity travel award! Your 4 years of work developing GW CRISPR screens in primary CAR-NK cells is paying off! Excited to see how your data will shape the future of NK cell therapy. MD Anderson Cancer Center #NK2025

Congrats to Nicholas Huntington and team on their Cancer Cell paper! CRISPR screens identify UBE2F and ARIH2 as key brakes on IL-15R signaling in NK cells. Targeting them improves NK & CAR-NK anti-tumor activity, uncovering promising targets for immunotherapy. #NKcells #CAR_NK #IL15

Thank you Dr Pisters for attending today’s EAB meeting and for your inspiring vision and steadfast support. Deepest thanks also to our extraordinary EAB members: Drs Carl June, Lewis Lanier, Nicholas Huntington Nicholas Huntington , John DiPersio, Helen Heslop, Keith Sullivan,